The US Food and Drug Administration (FDA) has approved Janssen Therapeutics' NS3/4A protease inhibitor 'Olysio (simeprevir)' for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with ...
The US FDA's Antiviral Drugs Advisory Committee has recommended approval for Medivir's investigational protease inhibitor simeprevir (TMC435) 150mg capsules for the treatment of genotype 1 chronic hepatitis C in adult patients with ...
Tags: Medivir, Hepatitis C Patients
Hemispherx Biopharma has filed an amended NDA with ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) for the use of Alferon N injection to treat Hepatitis C patients in Argentina. ANMAT has previously approved ...
Tags: Hemispherx Biopharma, Amended NDA, Alferon N Injection, ANMAT
GlaxoSmithKline's (GSK) Promacta has won FDA approval as thrombocytopenia therapy in chronic hepatitis C patients. Promacta, brand name of eltrombopag in the US, will enable thrombocytopenia patients suffering from chronic hepatitis C ...
Tags: FDA approval, thrombocytopenia therapy, chronic hepatitis C